Streetbeat News

Revenues

INGN

Inogen has projected its FY24 revenue to be between $325 million and $330 million, surpassing the estimated $322.75 million.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 9:56 pm

EML

Eastern Co (NASDAQ:EML) reported a 40% increase in Q2 earnings per share to $0.56, up from $0.40 YoY. Sales also rose by 7.04% to $73.15 million from $68.34 million YoY.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 9:55 pm

GORO

Gold Resource (AMEX:GORO) reported Q2 2024 GAAP EPS of $(0.01) and sales of $31.228 million, significantly beating the analyst estimate of $17.649 million. This represents a 25.88% increase over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 9:54 pm

FPAY

FlexShopper (NASDAQ:FPAY) reported Q2 2024 GAAP EPS of $(0.13), beating the $(0.14) estimate, but sales of $31.759M missed the $32.597M estimate. Sales increased by 29.46% year-over-year.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 9:53 pm

EBS

Emergent BioSolutions has updated its total revenue range for the fiscal year from $1 billion-$1.1 billion to $1.05 billion-$1.125 billion, surpassing the estimated $1.03 billion.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 9:53 pm

FOA

Finance of America (NYSE:FOA) reported Q2 2024 adjusted EPS of $(0.05), beating the analyst estimate of $(0.17) by 70.59%. The company also reported sales of $79.039 million, surpassing the $68.750 million estimate by 14.97%. This marks a 170.64% increase over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 9:52 pm

AGIO

Agios Pharmaceuticals is set to receive $1.1 billion in milestone payments following the FDA approval of Vorasidenib. The payments include $905 million from Royalty Pharma and $200 million from Servier, expected in Q3 2024. This will boost Agios' pro-forma cash position to $1.7 billion as of June 30, 2024, enabling the company to prepare for potential launches of PYRUKYND® (Mitapivat) in Thalassemia in 2025 and Sickle Cell Disease in 2026, and to drive pipeline progress.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 9:51 pm

REAL

RealReal (NASDAQ:REAL) reported Q2 2024 adjusted EPS of $(0.13), beating the $(0.14) estimate. Sales were $144.934M, surpassing the $139.749M estimate and showing a 10.76% increase from last year's $130.855M.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 9:49 pm

SU

Suncor Energy (NYSE:SU) reported strong Q2 earnings, with EPS of $0.93 beating estimates by 20.78% and sales of $9.53 billion surpassing expectations by 1.51%. This marks significant year-over-year growth in both earnings and sales.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 9:49 pm

GLRE

Greenlight Capital Re (NASDAQ:GLRE) reported Q2 earnings of $0.23 per share, missing the analyst consensus estimate of $0.25 by 8%. This represents an 82.58% decrease from $1.32 per share in the same period last year. Sales were $174.86 million, down 7.82% from $189.69 million YoY.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 9:48 pm